Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
Wils J., Sahmoud T., Sobrero A., Bleiberg H., Ahmedzai S., Blazeby J., Blijham G., Conroy T., Cunningham D., Curran D., Díaz-Rubio E., Ducreux M., Evans J., Glimelius B., Hutchinson G., Kerr D., Kiebert G., Köhne H., Labianca R., Langendijk R., Nitti D., Nordlinger B., Rougier P., Scheithauer W., Therasse P.
During the last few years several factors have contributed to an increasing change in the medical treatment of advanced colorectal cancer. Among them are the more general acceptance of the impact of chemotherapy on quality of life and survival in first as well as in second-line treatment, the introduction of new drugs and the definition of novel endpoints which can roughly be defined as "patient benefit". For this reason the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group (GITCCG) felt it was appropriate to organize a workshop with experts from different countries and national groups to discuss in depth several aspects concerning the treatment of patients with advanced colorectal cancer.